Articles Tagged With: hematoma
-
Cerebral Amyloid Angiopathy and Brain Hemorrhage
When comparing the time course of hematoma expansion between deep hematomas and lobar hematomas from cerebral amyloid angiopathy (CAA) and other etiologies, lobar hematomas from CAA show greater expansion and a longer period of risk for hematoma growth compared to deep hematomas.
-
Atorvastatin and Low-Dose Dexamethasone for Treatment of Chronic Subdural Hematoma
Chronic subdural hematoma is a common cause of serious neurological morbidity and mortality in the elderly population. Atorvastatin has both an anti-inflammatory effect and the ability to mobilize endothelial progenitor cells, which assist in vascular repair. The investigators proposed that adding a low dose of dexamethasone to atorvastatin treatment might enhance the anti-inflammatory benefits without causing the side effects associated with high doses of corticosteroids.
-
Tranexamic Acid in Patients with Intracerebral Hemorrhage Does Not Improve Outcomes
Primary intracerebral hemorrhage is a major cause of severe neurological disability and carries a high rate of death. Tranexamic acid was tested in a study of 2,325 patients with intracerebral hemorrhage within eight hours of symptom onset, but did not significantly improve neurological outcome.
-
Clinical Features of Subdural Fluid Collections With Intracranial Hypotension
Clinical features of patients with spontaneous intracranial hypotension and bilateral subdural fluid collections differ from patients who sustained previous head trauma vs. those with cerebrospinal fluid leaks.
-
Clinical Outcomes After Oral Anticoagulant-Associated Intracerebral Hematoma
In this meta-analysis of multiple observational studies, clinical outcomes after oral anticoagulant-associated intracerebral hematoma were similar for those associated with vitamin K antagonists or the new class of direct oral anticoagulants.
-
Treatment of Chronic Subdural Hematoma With Atorvastatin
-
Treatment of Intracerebral Hemorrhage Guided by the ‘Spot Sign’
Although the “spot sign” is a predictor of early hematoma expansion, selective treatment of this group with aggressive antihypertensive therapy did not alter hematoma size or neurological outcome.